Q1 2026
Released May 12, 2026, after the close
10-Q filed May 12, 2026, 42 days after period end · 0001357459-26-000010
Q1 2026 · 10-Q
Revenue$0.00$0.00 — vs Q1 2025no prior Q4 2025 on file
Net Income-$9.60M-$9.60M N/M vs Q1 2025N/M vs Q4 2025
EPS Diluted-$0.05-$0.05 N/M vs Q1 2025no prior Q4 2025 on file
Operating Income-$10,748,000N/M
Operating Cash Flow-$3,890,000N/M
What the release said
The release
Same quarter
| Metric | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $250.00K |
| Net Income | -$9.60M | -$2.23M | -$3.53M | -$2.34M |
| EPS Diluted | -$0.05 | -$0.47 | -$4.59 | -$8.13 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Palisade Bio, Inc. · CIK 1357459 · Engraved from SEC EDGAR